Sarepta Therapeutics reported $1.08B in Stock for its fiscal quarter ending in September of 2025.





Stock Change Date
Acadia Pharmaceuticals USD 29.1M 2.97M Sep/2025
Agios Pharmaceuticals USD 32.03M 1.19M Sep/2025
Alnylam Pharmaceuticals USD 75.38M 3.7M Sep/2025
Amgen USD 6.22B 121M Dec/2025
Biogen USD 2.21B 64.9M Sep/2025
BioMarin Pharmaceutical USD 1.38B 42M Sep/2025
Daiichi Sankyo JPY 608.55B 93.64B Sep/2025
Eli Lilly USD 12.18B 1.17B Sep/2025
Gilead Sciences USD 1.78B 40M Sep/2025
Incyte USD 83.45M 24K Sep/2025
Insmed USD 120.96M 13.36M Sep/2025
Ionis Pharmaceuticals USD 10.47M 1.99M Sep/2025
Moderna USD 332M 92M Sep/2025
Neurocrine Biosciences USD 69.3M 12.4M Sep/2025
Pfizer USD 11.47B 201M Sep/2025
PTC Therapeutics USD 52.69M 18.63M Sep/2025
Regeneron Pharmaceuticals USD 3.2B 53.6M Dec/2025
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 22.69B 1.81B Dec/2025
Sarepta Therapeutics USD 1.08B 83.13M Sep/2025
Ultragenyx Pharmaceutical USD 52.2M 5.7M Sep/2025
Vertex Pharmaceuticals USD 1.63B 127.5M Sep/2025